All
Cabometyx-Tecentriq Combo Fails to Improve Survival in Patients With Liver Cancer
March 15th 2022The combination of Cabometyx and Tecentriq failed to improve overall survival in patients with advanced hepatocellular carcinoma, the most common type of primary liver cancer, compared with single-agent Tecentriq or Nexavar.
Male Cancer Caregivers Navigate A Gauntlet of Challenges, Often Under The Cover of Darkness
March 15th 2022Regardless of a man’s age, providing care to a partner or family member with cancer has been shown to take a drastic toll on their health. To make matters worse, research shows many men struggle in silence.
Multiple Myeloma is Being Diagnosed More Often in Younger Patients, But The Reasons Why Are Unclear
March 14th 2022As more and more people in their 20s and 30s begin to receive diagnoses of multiple myeloma, a type of blood cancer, one expert stresses that continued research to improve survival in this patient population is critical.
CAR-T Cell Therapies Offer ‘An Opportunity for Majority of Patients’ With Lymphoma to Be Treated
March 14th 2022Unlike stem cell transplant, which has strict eligibility criteria, the majority of patients with blood cancer may be able to receive CAR-T cell therapy, regardless of other comorbidities, explained an expert.
FDA Approves Lynparza for Treatment of Certain Patients With High-Risk, Early-Stage Breast Cancer
March 11th 2022The FDA’s decision to OK Lynparza is based on data from the OlympiA trial, which showed that Lynparza reduced the risk of invasive breast cancer recurrences, second cancers or death by 42% versus placebo after initial treatment with chemotherapy.